GPD1 Antibody

What is GPD1 and why is it important in research?

GPD1 (Glycerol-3-phosphate dehydrogenase 1) is a cytoplasmic enzyme that belongs to the NAD-dependent glycerol-3-phosphate dehydrogenase family. Its C-terminal domain contains multiple helical structures for binding the substrate DHAP, while its N-terminal domain contains a β-folded core for binding NADH. GPD1 plays a crucial role in the conversion of dihydroxyacetone phosphate (DHAP) and reduced nicotinamide adenine dinucleotide (NADH) to glycerol-3-phosphate (G3P) and NAD+. This enzyme is significant in research due to its involvement in the transport of reducing equivalents across mitochondrial membranes and in triacylglycerol synthesis, making it relevant for studies in metabolism, cancer, and various diseases .

What are the typical applications for GPD1 antibodies in research?

GPD1 antibodies are widely used in multiple research applications, primarily:

These applications allow researchers to detect and quantify GPD1 protein levels in various sample types, including tissue samples and cell lines, particularly from liver, heart, and cultured cells such as HepG2 .

What species reactivity can be expected from most GPD1 antibodies?

Most commercially available GPD1 antibodies show reactivity with human, mouse, and rat samples. For example, the 13451-1-AP antibody has been tested and confirmed to react with proteins from all three species. When selecting an antibody for your research, it's essential to verify the specific reactivity profile as this can vary between products from different manufacturers .

What are the optimal conditions for Western blotting when using GPD1 antibodies?

For optimal Western blotting with GPD1 antibodies, the following protocol is recommended based on published research:

• Prepare 12% acrylamide gels for SDS-PAGE with approximately 20 μg protein per lane.

• Perform semi-dry electrophoretic transfer onto positively charged nitrocellulose membranes (20 minutes at 15V) using a buffer containing 48 mM Tris (pH 9.2), 39 mM glycine, 20% (v/v) methanol, and 0.0375 g/l SDS.

• Block membranes in TBS-T buffer (25 mM Tris-HCl pH 7.2, 150 mM NaCl, 0.1% Tween 20) with 5% nonfat dry milk for 1 hour at room temperature.

• Incubate with primary anti-GPD1 antibody (dilution range 1:750-1:1000, depending on the specific antibody) overnight at 4°C.

• Wash three times with TBS-T and incubate with appropriate HRP-labeled secondary antibody for 1 hour at room temperature.

• Visualize protein bands using an enhanced chemiluminescence detection system.

• For normalization, use β-actin (typical dilution 1:1000) as an internal control .

How can I optimize immunofluorescence experiments when using GPD1 antibodies?

For successful immunofluorescence experiments with GPD1 antibodies:

• Start with cells that have high endogenous GPD1 expression (HepG2 cells are recommended as they show positive IF/ICC detection).

• Use appropriate fixation methods (4% paraformaldehyde for 15 minutes is often suitable).

• Test a range of antibody dilutions, beginning with the recommended range of 1:20-1:200.

• Include proper negative controls (omitting primary antibody) and positive controls (cells known to express GPD1, such as liver-derived cell lines).

• Consider titration experiments to determine the optimal antibody concentration for your specific experimental system.

• If working with tissues rather than cells, ensure appropriate antigen retrieval steps are included in your protocol .

What controls should be included when validating novel GPD1 variants using antibody-based detection methods?

When validating novel GPD1 variants using antibody-based detection methods, several critical controls should be included:

• Wild-type GPD1 expression construct as a positive control

• Empty vector as a negative control

• Housekeeping protein (such as GAPDH) for normalization

• Expression of the variant GPD1 construct

For example, in a study identifying a novel heterozygous GPD1 missense variant (p.K327N), researchers constructed both wild-type GPD1 and GPD1 K327N plasmids, transfected them into HEK-293T cells, and compared protein expression using Western blotting with anti-Flag antibody (for tagged constructs) and anti-GAPDH for normalization. This approach allows for direct comparison between wild-type and variant protein expression, stability, and potential functional differences .

How is GPD1 expression altered in cancer, and what methodologies are best for studying these changes?

GPD1 expression is significantly altered in several cancer types, particularly breast cancer. Studies have shown that GPD1 protein levels are frequently downregulated in breast tumor tissues compared to healthy breast tissues. The most effective methodology for studying these changes includes:

• Western blotting analysis of protein pools prepared from different cancer subtypes

• Comparison of protein expression between:

  • Healthy breast (BH) vs. breast tumor (BT) tissues

  • Healthy lymph nodes (LH) vs. metastatic lymph nodes (LM)

What is the relationship between GPD1 and metformin in cancer treatment, and how can antibodies help investigate this connection?

GPD1 has been found to enhance the anticancer effects of metformin, a drug widely used for treating type 2 diabetes that also shows promise in cancer treatment. Research indicates that GPD1 overexpression significantly enhances metformin's ability to suppress cancer cell proliferation both in vitro and in vivo. The mechanism involves:

• Increased total cellular glycerol-3-phosphate concentration through the combined action of GPD1 overexpression and metformin treatment

• Inhibition of mitochondrial function

• Increased reactive oxygen species and mitochondrial structural damage

GPD1 antibodies play a crucial role in investigating this connection by allowing researchers to:

• Quantify GPD1 expression levels in different cancer cell lines

• Correlate GPD1 expression with response to metformin treatment

• Monitor changes in GPD1 levels during treatment

• Validate GPD1 overexpression in experimental models

This research suggests that patients with increased GPD1 expression in tumor cells may respond better to metformin therapy, potentially leading to more personalized cancer treatment approaches .

How can GPD1 antibodies be used to study the role of GPD1 in hypertriglyceridemia?

GPD1 has been associated with hypertriglyceridemia, a condition characterized by elevated triglyceride levels in the blood. To study this association, researchers can use GPD1 antibodies in several approaches:

• Western blotting to compare GPD1 expression levels in liver samples from patients with and without hypertriglyceridemia

• Immunohistochemistry to examine tissue distribution and localization of GPD1 in affected tissues

• Immunoprecipitation followed by mass spectrometry to identify GPD1 interacting partners in lipid metabolism pathways

• In vitro studies with wild-type and mutant GPD1 constructs to assess functional differences

When investigating novel GPD1 variants associated with hypertriglyceridemia, researchers should perform both genomic analysis (exome sequencing, PCR amplification, and Sanger sequencing) and functional protein studies using antibody-based detection methods. For instance, a study identified a novel heterozygous GPD1 missense variant (p.K327N) using exome sequencing, which was then validated through repeated Sanger sequencing and functional analysis in transfected HEK-293T cells using Western blotting with appropriate antibodies .

How should researchers interpret variations in GPD1 band patterns observed in Western blotting?

When interpreting variations in GPD1 band patterns in Western blotting, researchers should consider several factors:

• Expected molecular weight range: The calculated molecular weight of GPD1 is 38 kDa (349 amino acids), but the observed range is typically 32-42 kDa .

• Multiple bands may represent:

  • Different isoforms (up to 2 different isoforms have been reported)

  • Post-translational modifications

  • Proteolytic degradation products

  • Non-specific binding

To properly interpret these variations:

• Always include positive controls (samples known to express GPD1, such as liver tissue)

• Use molecular weight markers to accurately determine band sizes

• Consider performing peptide competition assays to confirm specificity

• If studying novel variants, compare band patterns between wild-type and variant proteins

• For quantitative comparisons, normalize to appropriate housekeeping proteins like β-actin or GAPDH

What strategies can help troubleshoot weak or absent signals when using GPD1 antibodies?

When facing weak or absent signals with GPD1 antibodies, consider the following troubleshooting approaches:

• Antibody dilution optimization:

  • For Western blotting, test a range from 1:500 to 1:3000

  • For immunofluorescence, try dilutions between 1:20 and 1:200

• Sample preparation improvements:

  • Ensure sufficient protein loading (20 μg per lane is recommended)

  • Use fresh samples and avoid repeated freeze-thaw cycles

  • Consider alternative lysis buffers that better preserve GPD1

• Detection system enhancements:

  • Use a more sensitive chemiluminescence substrate

  • Increase exposure time (while monitoring background)

  • Consider signal amplification systems

• Expression considerations:

  • Verify GPD1 expression in your sample type (highest in liver tissue)

  • Use positive controls (HepG2 cells, mouse/rat liver tissue)

  • Consider tissue-specific expression patterns

How can researchers validate the specificity of GPD1 antibodies in their experimental systems?

Validating GPD1 antibody specificity is crucial for reliable research results. Recommended validation approaches include:

• Knockout/knockdown controls:

  • Compare samples with GPD1 knockdown (siRNA/shRNA) or knockout (CRISPR-Cas9) to wild-type samples

  • Expected result: Reduced or absent signal in knockdown/knockout samples

• Overexpression controls:

  • Compare samples overexpressing GPD1 to empty vector controls

  • Expected result: Increased signal intensity in overexpression samples

• Peptide competition assays:

  • Pre-incubate antibody with the immunizing peptide before application

  • Expected result: Blocked or significantly reduced signal

• Multiple antibody validation:

  • Use different antibodies targeting different epitopes of GPD1

  • Expected result: Consistent detection pattern across antibodies

• Cross-species validation:

  • Test antibody reactivity in samples from different species (human, mouse, rat)

  • Expected result: Detection pattern consistent with known cross-reactivity